# LivaNova PLC (LIVN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $81.92, market value $4.5 billion.

## Valuation
- **P/E (trailing): 24.2×** (5-yr avg 100.8×, 3-yr avg 100.8×). LivaNova PLC trades at 24.2× trailing earnings, well below its own five-year average of 100.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.5×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.1×**. Each dollar of revenue is priced at 3.1×.
- **Price / book: 3.4×**. The shares trade at 3.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.3%** (5-yr avg 3.0%). Free cash flow equals 3.3% of the market value, in line with its five-year average of 3.0%.
- **Earnings yield: 4.1%**. The inverse of the P/E: 4.1% of the price is earned each year.

## Profitability
- **Gross margin: 68.1%**. LivaNova PLC keeps 68.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 12.7%**. 12.7% of revenue is left after running the business.
- **Net margin: -17.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -20.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 15.7%**. Return on all capital, debt included, is 15.7%: comfortably above what that capital costs.
- **Return on assets: 7.2%**. Each dollar of assets produces 7.2% of profit.

## Growth
- **Revenue growth (1 yr): 10.7%** (3-yr 10.8%/yr, 5-yr 8.2%/yr). Revenue grew 10.7% over the last year, against 8.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -483.6%**. Earnings per share fell 483.6%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 58.6%/yr**. Free cash flow has compounded at 58.6% a year over three years.

## Financial health
- **Debt to equity: 0.31**. Debt is 0.31 times equity: a conservative balance sheet.
- **Altman Z-score: 3.35**. A Z-score of 3.35 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. LivaNova PLC does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover LivaNova PLC; the consensus is buy, with an average price target of $89.10 (+9% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 40.9%** (YTD 33.1%, 3-mo 13.2%). The shares are up 40.9% over twelve months including dividends.
- **From 52-week high: -4.5%** (67.8% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.10** (volatility 37%). Beta of 1.10 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LIVN · Page: https://foliofundamentals.com/stocks/livn

Not investment advice.